Whole genome sequencing
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- DNA
- End of Treatment
- Hartwig Medical Database
- Hartwig Medical Foundation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud
In search of the optimal treatment strategy for glioblastoma
Patients with recurrent glioblastoma have an unfavorable outlook and few treatment options. The recently launched GLOW study should change this …
GLOW: working toward more treatment options for glioblastoma
The outlook for patients with glioblastoma has been unfavorable for years, and treatment options remain limited. That is a reason …
Collaboration for future-proof diagnostics and to accelerate research
Complete analysis of the DNA of children with cancer offers many possibilities. It maps out all possible targeted treatment options …
22 impactful scientific publications in 2022
In 2022, research groups from all over the world published 22 scientific papers in which data from the Hartwig Medical …
Whole genome sequencing is reliable, has added value, and can be embedded perfectly into everyday pathology diagnostics
Source: website Netherlands Cancer Institute With the rapidly expanding tableau of (increasingly tumor-agnostic) targeted therapies, genome-driven cancer care has become …
In the media: Rarity – Personalised cancer treatment – fact not fiction
Imagine a world in which each person’s cancer is treated with a personalised, targeted medical treatment regimen. A world in …
Complete DNA analysis for young adults with cancer
KWF finances the expansion of the infrastructure for cancer research in young adults with almost 4.5 million euros. These are …
Single WGS analysis of metastases is sufficient in most cases
DNA analysis of the tumor is of crucial importance to determine treatment options for patients with metastasized lung cancer. But …
Actionable metastatic cancer genome is remarkably stable over time, despite treatment with drugs
A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be …
ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk …
New CPoC grant awarded: GLOW – GLioblastoma targeted treatment Option maximisation by WGS
Oncode Institute has announced that the 13th grant within the Clinical Proof of Concept programme has been awarded. Oncode Investigator …
Whole Genome Sequencing for cancer diagnostics clinically validated
Scientific research has demonstrated that Whole Genome Sequencing (WGS) is at least as reliable as routine diagnostic procedures. Clinical Molecular …
Videos
From biopsy to patient report
The comprehensive DNA test can provide patients with cancer with more opportunities for treatment. Using the technique of Whole Genome …
Read more
What does Hartwig Medical Foundation do?
Hartwig Medical Foundation is a unique initiative that makes possible progress in the research of treatment of cancer in the …
Read more
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.